title: Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.
abstract: Recent successes in immunotherapeutic strategies are being investigated to combat cancers that have less than ideal responses to standard of care treatment, such as non-small-cell lung cancer. In this paper, we summarize concepts and the current status of immunotherapy for non-small cell lung cancer, including salient features of the major categories of immunotherapy-monoclonal antibody therapy, immune checkpoint blockade, immunotoxins, anticancer vaccines, and adoptive cell therapy.
authors.affiliation: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Marissa
authors.initials: M
authors.lastname: Mayor
authors.affiliation: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Neng
authors.initials: N
authors.lastname: Yang
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York University, New York, NY, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Sterman
authors.affiliation: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: David R
authors.initials: DR
authors.lastname: Jones
authors.affiliation: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA adusumip@mskcc.org.
authors.forename: Prasad S
authors.initials: PS
authors.lastname: Adusumilli
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002986:Clinical Trials as Topic; D005818:Genetic Engineering; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000628:therapy*; D051379:Mice
chemical_list: D000911:Antibodies, Monoclonal
keywords: Adoptive cell therapy; Antibody therapy; Chimeric antigen receptor; Lung cancer; PD-1/PD-L1 blockade